Dossier assessment

Capmatinib (advanced NSCLC with METex14 skipping mutation) - Benefit assessment according to §35a Social Code Book V

Status
Status: Commission completed
Project no.
A22-87
Last updated

Report documents

  1. Extract of dossier assessment

    Capmatinib (advanced NSCLC with METex14 skipping mutation) - Benefit assessment according to §35a Social Code Book V

    published on
    Document type
    PDF document, 450 kB, EN, not accessible
  2. Dossier assessment

    Capmatinib (advanced NSCLC with METex14 skipping mutation) - Benefit assessment according to §35a Social Code Book V

    published on
    Document type
    PDF document, 760 kB, DE, not accessible

Dossier assessment

Indication:

Adults with advanced non-small cell lung cancer with METex14 skipping alterations

Result of dossier assessment:
  • Patients after first-line therapy with a PD-1/PD-L1 antibody as monotherapy: added benefit not proven
  • Patients after first-line therapy with platinum-containing chemotherapy: added benefit not proven
  • Patients after first-line therapy with a PD-1/PD-L1 antibody in combination with platinum-containing chemotherapy or after sequential therapy with a PD-1/PD-L1 antibody and platinum-containing chemotherapy: added benefit not proven

Project details

Project no.
A22-87
Commission
Commission awarded on 17.08.2022 by the Federal Joint Committee (GBA).
Report type
Dossier assessment
Status
Commission completed
Department/Division
Drug Assessment
Topic
Cancer
Note

After completion of the assessment by IQWiG the Federal Joint Committee (GBA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the GBA website.

Contact

Info Service (German)

Subscribe to daily updated information on projects, calls for tender, current vacancies and events as well as our press releases.

Register

Contact form

Questions about commissions, publications and press releases can be sent to us via this form.

Contact form